quibim.aiCrawled Nov 11, 2026
QP-Prostate, QP-Brain, QP-Liver, QP-Lung, QP-Breast and QP-Insights — AI tools for MRI, CT and PET radiology workflows.
AI for brain MRI: volumetry of 132 regions, white-matter lesion quantification and longitudinal tracking. CE, UKCA and 510(k) cleared.
AI software for breast MRI: automated lesion detection, segmentation and characterization
Scientific publications: https://doi.org/10.1186/s13550-024-01172-9
A study examined how 18F-FDG PET/CT imaging, clinical data, and genomic parameters—individually or combined—predict complete response to first-line treatment in newly diagnosed diffuse large B-cell lymphoma (DLBCL).
Scientific publications: https://pubmed.ncbi.nlm.nih.gov/40061893/
Quibim launches CE and UKCA marked QP-Breast to transform breast cancer MRI interpretation across Europe and UK
QP-Prostate Receives Health Canada Licence, Expanding Quibim’s Reach to Canada
Quibim announces QP-Prostate availability through Precision Imaging Network, part of Microsoft’s diagnostic imaging and radiology solutions
Latest Quibim press releases, partnerships and corporate news. AI for medical imaging — radiology, biopharma and clinical research milestones.
Quibim employs over 90 AI, radiology, and life-sciences specialists across Valencia, Madrid, Barcelona, New York, and Cambridge (UK).
Quibim’s leadership, board, and advisors include AI, radiology, regulatory, and life-sciences experts based in Valencia, New York, and London.
Quibim, founded in Valencia, brings AI to medical imaging through QP-* products and the QP-Insights platform. 90+ specialists, 230+ partner sites.
EU Horizon, SBRI Healthcare, INNVIERTE and other grants and awards backing Quibim's research in AI applied to medical imaging.
The Quibim Platform manages, harmonizes, and analyzes multi-omics imaging data, integrating with PACS.
Encryption at rest and in transit, data residency, sub-processors and incident response. Quibim's security posture in detail.
Quibim builds AI tools that turn MRI, CT and PET data into actionable predictions for hospitals and biopharma. Trusted in 470+ centers worldwide.
